Visual acuity outcomes after anti-VEGF treatment for neovascular age-related macular degeneration: AREDS2 Report Number 19

PURPOSE: To analyze best-corrected visual acuity (BCVA) outcomes after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). DESIGN: Prospective cohort study of participants enrolled in a clinical trial of oral supplements and receiving anti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ophthalmol Retina
Autores principales: Keenan, Tiarnan D., Vitale, Susan, Agrón, Elvira, Domalpally, Amitha, Antoszyk, Andrew N., Elman, Michael J., Clemons, Traci E., Chew, Emily Y.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6904530/
https://ncbi.nlm.nih.gov/pubmed/31395505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oret.2019.06.001
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares